Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause.
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
28
8
2019
medline:
29
1
2020
entrez:
28
8
2019
Statut:
ppublish
Résumé
Genitourinary syndrome of menopause is a condition comprising the atrophic symptoms and signs women may experience in the vulvovaginal and bladder-urethral areas as a result of the loss of sex steroids that occurs with menopause. It is a progressive condition that does not resolve without treatment and can adversely affect a woman's quality of life. For a variety of reasons, many symptomatic women do not seek treatment and, of those who do, many are unhappy with their options. Additionally, many healthcare providers do not actively screen their menopausal patients for the symptoms of genitourinary syndrome of menopause. In this review, we discuss the clinical presentation of genitourinary syndrome of menopause as well as the treatment guidelines recommended by the major societies engaged in women's health. This is followed by a review of available treatment options that includes both hormonal and non-hormonal therapies. We discuss both the systemic and vaginal estrogen products that have been available for decades and remain important treatment options for patients; however, a major intent of the review is to provide information on the newer, non-estrogen pharmacologic treatment options, in particular oral ospemifene and vaginal prasterone. A discussion of adjunctive therapies such as moisturizers, lubricants, physical therapy/dilators, hyaluronic acid, and laser therapy is included. We also address some of the available data on both the patient and healthcare providers perspectives on treatment, including cost, and touch briefly on the topic of treating women with a history of, or at high risk for, breast cancer.
Identifiants
pubmed: 31452067
doi: 10.1007/s40266-019-00700-w
pii: 10.1007/s40266-019-00700-w
pmc: PMC6764929
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
897-908Références
Parish SJ, Nappi RE, Krychman ML, Kellogg-Spadt S, Simon JA, Goldstein JA, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5:437–47. https://doi.org/10.2147/ijwh.s44579 .
doi: 10.2147/ijwh.s44579
pubmed: 23935388
pmcid: 3735281
Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Menopause. 2014;21(10):1063–8. https://doi.org/10.1097/gme.0000000000000329 .
doi: 10.1097/gme.0000000000000329
pubmed: 25160739
Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286–91. https://doi.org/10.1080/13697137.2018.1446930 .
doi: 10.1080/13697137.2018.1446930
pubmed: 29553288
Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA): results from an international survey. Climacteric. 2012;15(1):36–44. https://doi.org/10.3109/13697137.2011.647840 .
doi: 10.3109/13697137.2011.647840
pubmed: 22168244
Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215(6):704–11. https://doi.org/10.1016/j.ajog.2016.07.045 .
doi: 10.1016/j.ajog.2016.07.045
pubmed: 27472999
Moral E, Delgado JL, Carmona F, Caballero B, Guillan C, Gonzalez PM, et al. The impact of genitourinary syndrome of menopause on well-being, functioning, and quality of life in postmenopausal women. Menopause. 2018;25(12):1418–23. https://doi.org/10.1097/gme.0000000000001148 .
doi: 10.1097/gme.0000000000001148
pubmed: 29944636
Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE. Vaginal Health in the United States: results from the Vaginal Health: Insights Views & Attitudes survey. Menopause. 2013;20(10):1043–8. https://doi.org/10.1097/GME.0b013e318287342d .
doi: 10.1097/GME.0b013e318287342d
pubmed: 23571518
Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V. Clarifying vaginal atrophy’s impact on sex and relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause. 2014;21(2):137–42. https://doi.org/10.1097/GME.0b013e318295236f .
doi: 10.1097/GME.0b013e318295236f
pubmed: 23736862
Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790–9. https://doi.org/10.1111/jsm.12190 .
doi: 10.1111/jsm.12190
pubmed: 23679050
Cumming GP, Herald J, Moncur R, Currie H, Lee AJ. Women’s attitudes to hormone replacement therapy, alternative therapy and sexual health: a web-based survey. Menopause Int. 2007;13(2):79–83. https://doi.org/10.1258/175404507780796424 .
doi: 10.1258/175404507780796424
pubmed: 17540139
Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018;25(11):1321–30. https://doi.org/10.1097/gme.0000000000001236 .
doi: 10.1097/gme.0000000000001236
pubmed: 30358729
Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas. 2016;91:42–50. https://doi.org/10.1016/j.maturitas.2016.05.015 .
doi: 10.1016/j.maturitas.2016.05.015
pubmed: 27451320
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
doi: 10.1001/jama.288.3.321
pubmed: 12117397
Simon JA. The Woman’s Health Initiative and one of many unintended consequences. Menopause. 2016;23(10):1057–9. https://doi.org/10.1097/gme.0000000000000749 .
doi: 10.1097/gme.0000000000000749
pubmed: 27623202
North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–53. https://doi.org/10.1097/gme.0000000000000921 .
doi: 10.1097/gme.0000000000000921
American College of Obstetrics and Gynecology. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202–16. https://doi.org/10.1097/01.aog.0000441353.20693.78 .
doi: 10.1097/01.aog.0000441353.20693.78
American College of Obstetrics and Gynecology. ACOG Practice Bulletin No. 126: management of gynecologic issues in women with breast cancer. Obstet Gynecol. 2012;119(3):666–82. https://doi.org/10.1097/aog.0b013e31824e12ce .
doi: 10.1097/aog.0b013e31824e12ce
Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol. 2018;36(5):492–511. https://doi.org/10.1200/jco.2017.75.8995 .
doi: 10.1200/jco.2017.75.8995
pubmed: 29227723
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011. https://doi.org/10.1210/jc.2015-2236 .
doi: 10.1210/jc.2015-2236
pubmed: 26444994
Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489–510. https://doi.org/10.1210/jc.2014-2260 .
doi: 10.1210/jc.2014-2260
pubmed: 25279570
Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50. https://doi.org/10.3109/13697137.2015.1129166 .
doi: 10.3109/13697137.2015.1129166
pubmed: 26872610
Simon JA, Goldstein I, Kim NN, Davis SR, Kellogg-Spadt S, Lowenstein L, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause. 2018;25(7):837–47. https://doi.org/10.1097/gme.0000000000001138 .
doi: 10.1097/gme.0000000000001138
pubmed: 29870471
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902. https://doi.org/10.1097/gme.0b013e3182a122c2 (quiz 3–4).
doi: 10.1097/gme.0b013e3182a122c2
North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155–72. https://doi.org/10.1097/gme.0000000000000546 (quiz 73–4).
doi: 10.1097/gme.0000000000000546
Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018;25(6):596–608. https://doi.org/10.1097/gme.0000000000001121 .
doi: 10.1097/gme.0000000000001121
pubmed: 29762200
US Food and Drug Administration. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms: recommendations for clinical evaluation. 2003. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071643.pdf ). Accessed 6 Dec 2017.
Jeffrey S. Estrogen formulations get FDA “black-box” warning. Medscape. 2003. https://www.medscape.com/viewarticle/785840 . Accessed 25 June 2019.
Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;8:CD001500. https://doi.org/10.1002/14651858.cd001500.pub3 .
doi: 10.1002/14651858.cd001500.pub3
North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3 Pt 1):355–69. https://doi.org/10.1097/gme.0b013e31805170eb (quiz 70–1).
doi: 10.1097/gme.0b013e31805170eb
Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc. 2017;92(12):1842–9. https://doi.org/10.1016/j.mayocp.2017.08.019 .
doi: 10.1016/j.mayocp.2017.08.019
pubmed: 29202940
Allergan USA. ALORA
Bayer HealthCare Pharmaceuticals Inc. Climara
Teva Pharmaceuticals USA Inc. ESTRADIOL- estradiol tablet. 2018. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4936878-1643-4e7f-9b0d-e4957935aef2 .
Allergan USA I. Femring
Pfizer. Premarin (conjugated estrogens) tablets: prescribing information. 2018. http://labeling.pfizer.com/showlabeling.aspx?id=131 . Accessed 12 Mar 2019.
Novartis Pharmaceuticals Corp. VIVELLE-DOT
Allergan USA I. Estrace
Pfizer. ESTRING
TherapeuticsMD Inc. Imvexxy (estradiol vaginal inserts) Prescribing Information (May). 2018. https://imvexxy.com/pi.pdf?utm_medium=dir_org&utm_source=dir_org&utm_campaign=undefined&utm_content=undefined&utm_term=dir_org .
Pfizer. Premarin (conjugated estrogens) vaginal cream: prescribing information. 2018. http://labeling.pfizer.com/showlabeling.aspx?id=132 . Accessed 12 Mar 2019.
Novo Nordisk Health Care AG. VAGIFEM
Duchesnay Inc. Osphena (ospemifene) tablets: prescribing information. 2019.
AMAG Pharmaceuticals. Intrarosa (prasterone) vaginal insert. Prescribing Information. 2018. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df731acd-7276-4fef-b037-bc7f30c112cb .
Parish SJ, Gillespie JA. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms. Postgrad Med. 2017;129(3):340–51. https://doi.org/10.1080/00325481.2017.1281083 .
doi: 10.1080/00325481.2017.1281083
pubmed: 28132583
Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010;13(2):132–40. https://doi.org/10.3109/13697130903305627 .
doi: 10.3109/13697130903305627
pubmed: 19863455
Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17(2):281–9. https://doi.org/10.1097/GME.0b013e3181b7c65f .
doi: 10.1097/GME.0b013e3181b7c65f
pubmed: 19779382
Kingsberg SA, Krychman ML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med. 2013;10(6):1567–74. https://doi.org/10.1111/jsm.12120 .
doi: 10.1111/jsm.12120
pubmed: 23534861
Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. 2018;10:387–95. https://doi.org/10.2147/ijwh.s158913 .
doi: 10.2147/ijwh.s158913
pubmed: 30104904
pmcid: 6074805
Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019;26(4):431–53. https://doi.org/10.1097/GME.0000000000001221 .
doi: 10.1097/GME.0000000000001221
pubmed: 30363010
Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147–56. https://doi.org/10.1097/aog.0000000000000526 .
doi: 10.1097/aog.0000000000000526
pubmed: 25415166
pmcid: 4855283
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;4:CD001500. https://doi.org/10.1002/14651858.cd001500.pub2 .
doi: 10.1002/14651858.cd001500.pub2
Weber MA, Kleijn MH, Langendam M, Limpens J, Heineman MJ, Roovers JP. Local oestrogen for pelvic floor disorders: a systematic review. PLoS One. 2015;10(9):e0136265. https://doi.org/10.1371/journal.pone.0136265 .
doi: 10.1371/journal.pone.0136265
pubmed: 26383760
pmcid: 4575150
Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2018;26(6):603–10. https://doi.org/10.1097/gme.0000000000001284 .
doi: 10.1097/gme.0000000000001284
pubmed: 30562320
pmcid: 6538478
Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11–20. https://doi.org/10.1097/gme.0000000000000956 .
doi: 10.1097/gme.0000000000000956
pubmed: 28816933
pmcid: 5734988
Constantine GD, Graham S, Lapane K, Ohleth K, Bernick B, Liu J, et al. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. Menopause. 2019;26(7):800–7. https://doi.org/10.1097/gme.0000000000001315 .
doi: 10.1097/gme.0000000000001315
pubmed: 30889085
pmcid: 6636806
Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med. 2018;178(5):681–90. https://doi.org/10.1001/jamainternmed.2018.0116 .
doi: 10.1001/jamainternmed.2018.0116
pubmed: 29554173
pmcid: 5885275
Pinkerton JV, Kaunitz AM, Manson JE. Not time to abandon use of local vaginal hormone therapies. Menopause. 2018;25(8):855–8. https://doi.org/10.1097/gme.0000000000001142 .
doi: 10.1097/gme.0000000000001142
pubmed: 29894370
Traish AM, Vignozzi L, Simon JA, Goldstein I, Kim NN. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev. 2018;6(4):558–71. https://doi.org/10.1016/j.sxmr.2018.03.005 .
doi: 10.1016/j.sxmr.2018.03.005
pubmed: 29631981
Bell RJ, Rizvi F, Islam RM, Davis SR. A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause. 2018;25(6):704–9. https://doi.org/10.1097/gme.0000000000001052 .
doi: 10.1097/gme.0000000000001052
pubmed: 29286987
Labrie F, Belanger A, Pelletier G, Martel C, Archer DF, Utian WH. Science of intracrinology in postmenopausal women. Menopause. 2017;24(6):702–12. https://doi.org/10.1097/gme.0000000000000808 .
doi: 10.1097/gme.0000000000000808
pubmed: 28098598
Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015;22(9):950–63. https://doi.org/10.1097/gme.0000000000000428 .
doi: 10.1097/gme.0000000000000428
pubmed: 25734980
Archer DF, Labrie F, Montesino M, Martel C. Comparison of intravaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 μg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol. 2017;174:1–8. https://doi.org/10.1016/j.jsbmb.2017.03.014 .
doi: 10.1016/j.jsbmb.2017.03.014
pubmed: 28323042
Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243–56. https://doi.org/10.1097/gme.0000000000000571 .
doi: 10.1097/gme.0000000000000571
pubmed: 26731686
Portman DJ, Goldstein SR, Kagan R. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review. Climacteric. 2019;22(1):65–72. https://doi.org/10.1080/13697137.2018.1535583 .
doi: 10.1080/13697137.2018.1535583
pubmed: 30554531
Simon JA, Altomare C, Cort S, Jiang W, Pinkerton JV. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health (Larchmt). 2018;27(1):14–23. https://doi.org/10.1089/jwh.2017.6385 .
doi: 10.1089/jwh.2017.6385
pmcid: 5771532
Di Donato V, Schiavi MC, Iacobelli V, D’Oria O, Kontopantelis E, Simoncini T, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part I: evaluation of efficacy. Maturitas. 2019;121:86–92. https://doi.org/10.1016/j.maturitas.2018.11.016 .
doi: 10.1016/j.maturitas.2018.11.016
pubmed: 30509753
Di Donato V, Schiavi MC, Iacobelli V, D’Oria O, Kontopantelis E, Simoncini T, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation of tolerability and safety. Maturitas. 2019;121:93–100. https://doi.org/10.1016/j.maturitas.2018.11.017 .
doi: 10.1016/j.maturitas.2018.11.017
pubmed: 30509754
Pinkerton JV, Pickar JH. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy. Menopause. 2016;23(2):215–23. https://doi.org/10.1097/gme.0000000000000523 .
doi: 10.1097/gme.0000000000000523
pubmed: 26418479
pmcid: 4927324
Caruso S, Cianci S, Amore FF, Ventura B, Bambili E, Spadola S, et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause. 2016;23(1):47–54. https://doi.org/10.1097/gme.0000000000000485 .
doi: 10.1097/gme.0000000000000485
pubmed: 26079974
Mueck AO, Ruan X, Prasauskas V, Grob P, Ortmann O. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric. 2018;21(2):140–7. https://doi.org/10.1080/13697137.2017.1421923 .
doi: 10.1080/13697137.2017.1421923
pubmed: 29381086
Kingsberg SA, Larkin L, Krychman M, Parish SJ, Bernick B, Mirkin S. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause. 2019;26(2):124–31. https://doi.org/10.1097/GME.0000000000001194 .
doi: 10.1097/GME.0000000000001194
pubmed: 30130293
American College of Obstetrics and Gynecology. ACOG Committee Opinion No. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):e93–6. https://doi.org/10.1097/aog.0000000000001351 .
doi: 10.1097/aog.0000000000001351
Barton DL, Sloan JA, Shuster LT, Gill P, Griffin P, Flynn K, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(2):643–50. https://doi.org/10.1007/s00520-017-3878-2 .
doi: 10.1007/s00520-017-3878-2
pubmed: 28921241
Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–61. https://doi.org/10.3109/13697137.2015.1124259 .
doi: 10.3109/13697137.2015.1124259
pubmed: 26707589
Herbenick D, Reece M, Hensel D, Sanders S, Jozkowski K, Fortenberry JD. Association of lubricant use with women’s sexual pleasure, sexual satisfaction, and genital symptoms: a prospective daily diary study. J Sex Med. 2011;8(1):202–12. https://doi.org/10.1111/j.1743-6109.2010.02067.x .
doi: 10.1111/j.1743-6109.2010.02067.x
pubmed: 21143591
World Health Organization. Use and procurement of additional lubricants for male and female condoms: WHO/UNFPA/FHI360 Advisory Note. 2012. https://apps.who.int/iris/bitstream/handle/10665/76580/WHO_RHR_12.33_eng.pdf?sequence=1&isAllowed=y .
Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE Survey. Clin Med Insights Reprod Health. 2014;8:23–30. https://doi.org/10.4137/cmrh.s14498 .
doi: 10.4137/cmrh.s14498
pubmed: 24987271
pmcid: 4071759
Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med. 2013;10(6):1575–84. https://doi.org/10.1111/jsm.12125 .
doi: 10.1111/jsm.12125
pubmed: 23574713
Jokar A, Davari T, Asadi N, Ahmadi F, Foruhari S. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: a randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2016;4(1):6–78.
Origoni M, Cimmino C, Carminati G, Iachini E, Stefani C, Girardelli S, et al. Postmenopausal vulvovaginal atrophy (VVA) is positively improved by topical hyaluronic acid application: a prospective, observational study. Eur Rev Med Pharmacol Sci. 2016;20(20):4190–5.
pubmed: 27831658
Mercier J, Morin M, Lemieux MC, Reichetzer B, Khalife S, Dumoulin C. Pelvic floor muscles training to reduce symptoms and signs of vulvovaginal atrophy: a case study. Menopause. 2016;23(7):816–20. https://doi.org/10.1097/gme.0000000000000620 .
doi: 10.1097/gme.0000000000000620
pubmed: 27219835
Arunkalaivanan A, Kaur H, Onuma O. Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J. 2017;28(5):681–5. https://doi.org/10.1007/s00192-017-3282-y .
doi: 10.1007/s00192-017-3282-y
pubmed: 28154914
Rabley A, O’Shea T, Terry R, Byun S, Louis Moy M. Laser therapy for genitourinary syndrome of menopause. Curr Urol Rep. 2018;19(10):83. https://doi.org/10.1007/s11934-018-0831-y .
doi: 10.1007/s11934-018-0831-y
pubmed: 30117032
US Food and Drug Administration. FDA warns against use of energy-based devices to perform vaginal ‘rejuvenation’ or vaginal cosmetic procedures: FDA Safety Communication. 2018. https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm615013.htm . Accessed 8 Mar 2019.
Gordon C, Gonzales S, Krychman ML. Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. Menopause. 2019;26(4):423–7. https://doi.org/10.1097/GME.0000000000001293 .
doi: 10.1097/GME.0000000000001293
pubmed: 30640806
Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233–8. https://doi.org/10.1016/j.maturitas.2010.08.001 .
doi: 10.1016/j.maturitas.2010.08.001
pubmed: 20828948
Shifren JL, Johannes CB, Monz BU, Russo PA, Bennett L, Rosen R. Help-seeking behavior of women with self-reported distressing sexual problems. J Womens Health (Larchmt). 2009;18(4):461–8. https://doi.org/10.1089/jwh.2008.1133 .
doi: 10.1089/jwh.2008.1133
Palma F, Xholli A, Cagnacci A. Management of vaginal atrophy: a real mess. Results from the AGATA study. Gynecol Endocrinol. 2017;33(9):702–7. https://doi.org/10.1080/09513590.2017.1309018 .
doi: 10.1080/09513590.2017.1309018
pubmed: 28391746
Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The women’s EMPOWER survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14(3):413–24. https://doi.org/10.1016/j.jsxm.2017.01.010 .
doi: 10.1016/j.jsxm.2017.01.010
pubmed: 28202320
Krychman M, Graham S, Bernick B, Mirkin S, Kingsberg SA. The women’s EMPOWER survey: women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. 2017;14(3):425–33. https://doi.org/10.1016/j.jsxm.2017.01.011 .
doi: 10.1016/j.jsxm.2017.01.011
pubmed: 28202319
Manson JE, Goldstein SR, Kagan R, Kaunitz AM, Liu JH, Pinkerton JV, et al. Why the product labeling for low-dose vaginal estrogen should be changed. Menopause. 2014;21(9):911–6. https://doi.org/10.1097/gme.0000000000000316 .
doi: 10.1097/gme.0000000000000316
pubmed: 25140698
Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016;19(2):188–97. https://doi.org/10.3109/13697137.2015.1107039 .
doi: 10.3109/13697137.2015.1107039
pubmed: 26581580